Why Pfizer Stock Tumbled on Tuesday

Source The Motley Fool

Tuesday was a fairly eventful news day for U.S. pharmaceutical sector company Pfizer (NYSE: PFE). It reported third-quarter earnings and updated investors about its relationship with an activist investor in its ranks. Neither of these occurrences impressed the market, however, and the company's share price dipped by more than 1%. That was on a day when the S&P 500 index closed in the black, albeit modestly at 0.2%.

Strong growth and twin beats weren't enough for investors

Well before market open, Pfizer unveiled those quarterly results. These showed that the company's revenue was $17.7 billion, for a strong 32% year-over-year improvement when factoring sales of Covid treatment Paxlovid and vaccine Comirnaty. If those two high-profile products are taken out of the calculation, the healthcare giant's top-line growth would have been 14%.

As for earnings, Pfizer's non-GAAP (adjusted) bottom line flipped into the black. The company earned a profit of just over $6 billion, quite a change from the $968 million loss in the year-ago period.

This meant a pair of convincing beats for the company. On average, analysts following Pfizer were expecting less than $15 billion for sales and a mere $0.62 per share in adjusted net income.

What likely overshadowed this for investors was remarks by CEO Albert Bourla on the analyst call discussing the quarter. Addressing criticism by recently arrived activist investor Starboard Value, Bourla said of Pfizer's recent spate of acquisitions that Starboard officials "claim that we wasted money with business development. We have a very different view. We think -- and our board thinks -- that the deals are transformational."

Bullish about the immediate future

Signaling confidence in that strategy and buttressed by those growth figures, Pfizer raised its revenue and profitability guidance for the entirety of 2024. It now feels it will earn $61 billion to $64 billion on the top line and post adjusted earnings of $2.75 to $2.95 per share. Both ranges are up from the previous guidance of $59.5 billion to $62.5 billion and $2.45 to $2.65, respectively.

Should you invest $1,000 in Pfizer right now?

Before you buy stock in Pfizer, consider this:

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Pfizer wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.

Consider when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $861,121!*

Stock Advisor provides investors with an easy-to-follow blueprint for success, including guidance on building a portfolio, regular updates from analysts, and two new stock picks each month. The Stock Advisor service has more than quadrupled the return of S&P 500 since 2002*.

See the 10 stocks »

*Stock Advisor returns as of October 28, 2024

Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Pfizer. The Motley Fool has a disclosure policy.

Disclaimer: For information purposes only. Past performance is not indicative of future results.
placeholder
Natural Gas sinks to pivotal level as China’s demand slumpsNatural Gas price (XNG/USD) edges lower and sinks to $2.56 on Monday, extending its losing streak for the fifth day in a row. The move comes on the back of China cutting its Liquified Natural Gas (LNG) imports after prices rose above $3.0 in June. It
Author  FXStreet
Jul 01, Mon
Natural Gas price (XNG/USD) edges lower and sinks to $2.56 on Monday, extending its losing streak for the fifth day in a row. The move comes on the back of China cutting its Liquified Natural Gas (LNG) imports after prices rose above $3.0 in June. It
placeholder
AMD gains as Northland says share gains likely to continueInvesting.com -- Shares of Advanced Micro Devices (AMD) (NASDAQ:AMD) rose on Monday during pre-market trading after analysts at Northland Capital Markets said that they believe that the company will report revenue at or above the high end of its guidance for the third quarter in a note dated Monday.
Author  Investing.com
Oct 28, Mon
Investing.com -- Shares of Advanced Micro Devices (AMD) (NASDAQ:AMD) rose on Monday during pre-market trading after analysts at Northland Capital Markets said that they believe that the company will report revenue at or above the high end of its guidance for the third quarter in a note dated Monday.
placeholder
Google Earnings Incoming: Antitrust Risks and AI Investments in the SpotlightInsights - On October 29, after U.S. market hours, Google’s parent company Alphabet (GOOGL) will release its Q3 2024 earnings report.
Author  Mitrade
22 hours ago
Insights - On October 29, after U.S. market hours, Google’s parent company Alphabet (GOOGL) will release its Q3 2024 earnings report.
placeholder
AMD Q3 Earnings Preview: Can Data Center Revenues Continue to Set Records?Insights - AMD (AMD.US) is set to release its Q3 FY2024 earnings on October 29. As one of the few companies capable of genuinely capturing market share from NVIDIA, AMD’s earnings report will be a focal point for the market.
Author  Mitrade
22 hours ago
Insights - AMD (AMD.US) is set to release its Q3 FY2024 earnings on October 29. As one of the few companies capable of genuinely capturing market share from NVIDIA, AMD’s earnings report will be a focal point for the market.
placeholder
Dogecoin (DOGE) Price Shows Strong Bullish Sentiment as Buyers Gain ControlDogecoin (DOGE) price is showing signs of bullish momentum, as recent technical indicators point toward potential gains. The Ichimoku Cloud, EMA lines, and DMI all suggest positive movement, though the strength of the trend is still uncertain.
Author  Beincrypto
18 hours ago
Dogecoin (DOGE) price is showing signs of bullish momentum, as recent technical indicators point toward potential gains. The Ichimoku Cloud, EMA lines, and DMI all suggest positive movement, though the strength of the trend is still uncertain.
goTop
quote